Aktieanalys

Cantargia: Nadunolimab Soon Ready for Leukaemia Trial - Redeye

{newsItem.title}

Redeye Publicerad: 27 Mar 08:46

Cantargia today reported the preparations for the clinical trial of nadunolimab in leukaemia is going according to plan. The trial is scheduled to commence this summer.

Länk till analysen i sin helhet: https://www.redeye.se/research/992719/cantargia-nadunolimab-soon-ready-for-leukaemia-trial?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt